ABSTRACT
INTRODUCTION
Estrous synchronization and artificial insemination remain the most important and widely applicable reproductive biotechnologies available for cattle. Use of artificial insemination in cattle has allowed the introduction of highly successful genetic improvement programs for increasing milk yield and has reduced the incidence of several diseases (PATTERSON et al., 2013) . Estrous control in cattle can be achieved by the administration of progesterone (pregn-4-ene-3,20-dione) during 5-9 days inhibiting the luteinizing hormone (LH) secretion (NEVES et al., 2010) . Currently available intravaginal inserts for estrous control of cattle comprise "Y" or "T" shaped silicone matrices containing homogenously dispersed progesterone (RATHBONE et al., 1998; RATHBONE et al., 2002) . Their objective is not only provide sustained release but to facilitate handling and application in the cattle.
Although silicone presents biocompatibility it is not considered biodegradable and the inserts must be removed after the dosage period. Studies have proven that silicone can be substituted by polymers that present both characteristics, biocompatibility and biodegradability, eg. poly (hydroxybutirateco-hydroxyvalerate) (PHBV) and poly (epsloncaprolactone) (PCL). (PIMENTEL, 2010) . LEIMANN et al. (2013) demonstrated that PHBV nanoparticles showed a capacity for rapid hydrolytical degradation with a pronounced decrease of the molecular weight (pH values, 2.5 and 7.0, at 4 and 37ºC). CHAWLA E AMIJI (2002) demonstrated that PCL nanoparticles were completely degraded after 36h in the presence of lipase. Therefore the use of these biodegradable and commercial evaluable polymers can be an interesting alternative to replace the silicone devices.
Biopolymer micro and nanoparticles have been proposed as an alternative to encapsulate progesterone (JAMEELA et al., 1998; LEMOS-SENNA et al., 1998; MATSUMOTO et al., 1999; LATHA et al., 2000; SILVA et al., 2006; SALEM, 2010) . It is worth noting that besides the controlled delivery, encapsulation also provides protection from premature degradation during handling and storage before use, enhancement of absorption and bioavailability, improved retention time inside the organism and improvement of intracellular penetration (KUMARI et al., 2010) .
Nanoparticles production technique must be flexible to obtain nanoparticle with different properties, enabling to modify the polymer matrix composition and to use pure polymer and blend or hybrid nanoparticles. This could result in different drug concentration inside the particles and modulated progesterone release in different hydrolysis rate (BAJPAI et al., 2008; CAN et al., 2011) . Polymer structure in the nanometer size range can be modified to better suit biocompatibility, bio-recognition and biological systems integration (WEST and HALAS, 2000) , which is a feasible way to reach polymer blend nanoparticles. An advantage about the miniemulsion/ solvent evaporation technique is that it does not require any chemical modification of the polymer structure and it is applicable to virtually any material that is sufficiently hydrophobic to be considered immiscible with water and that forms a solid phase after solvent evaporation (KIETZKE et al., 2003) . Furthermore, progesterone has no solubility in water making this the ideal system for its encapsulation.
In this research progesterone-loaded blend nanoparticles produced by miniemulsion/ solvent evaporation technique with PHBV, PCL and PLLA were characterized within their morphology, z-average size (Dz) and polydispersion index (PDI), progesterone recovery yield (RY%) and encapsulation efficiency (EE%) as well as the chemical interactions between the polymeric matrices and the drug.
MATERIAL AND METHODS

Material
PHBV (8.2 HV mol%; Mw 255,660g.mol
) and PCL were kindly supplied by PHB Industrial S.A. Sodium borohydride (NaBH 4 ), chloroform, hexane, and methanol (Nuclear, P.A.) were used in the molecular weight reduction of PHBV. The dimer L-lactide (Purasorb L, Purac), tin II 2 ethylhexanoate (catalyst, Sigma Aldrich, 99.5% purity), gaseous nitrogen (99.9% purity), methanol, chloroform and tetrahydrofuran were used for PLLA synthesis. All reactants were used as received without further purification. Progesterone was supplied by INDEX Farmacêutica (99.98%) and lecithin (Alfa Aesar) was used as surfactant.
PHBV Purification and molecular weight reduction
To purify PHBV and reduce its molecular weight the procedure described by LEIMANN et al. (2013) was adopted. Briefly, PHBV was solubilized in chloroform, precipitated in hexane and dried at 60°C. After that PHBV (15g) was dissolved in chloroform (400ml) and NaBH 4 (130mg) was dissolved in methanol (44ml). Both solutions were mixed and stirred during 6h at room temperature. Finally, PHBV was precipitated in cold methanol, filtered under vacuum and dried at 60°C.
PLLA Synthesis
L-lactide ring opening polymerization was carried out as described by NIJENHUIS et al. (1992) and HYON et al. (1997) with some modifications. L-lactide and catalyst were allowed to react in ampoules in an oil bath at 140°C for 24 hours. After that the ampoules were immediately quenched in cold methanol (10°C). The L-lactide/catalyst molar ratio used was 5,000mol L-lactide /mol catalyst as suggested by HYON et al. (1997) .
Nanoparticles preparation
Nanoparticles of pure PHBV, PCL and PLLLA and blend nanoparticles of PHBV/PCL and PHBV/PLLA were prepared as described by MUSYANOVYCH et al. (2008) . The organic phase was prepared dissolving lecithin (0.175g), polymer (0.3g) and progesterone (5mg or 0mg) in chloroform (10g). The organic phase was then added to the water (24g) and stirred (1000rpm) for 60min. Miniemulsification was performed in an ice bath using sonication for 180s at 100% amplitude in a pulsed regime (30s sonication, 10s pause) using a Fisher-Scientific -Ultrasonic Dismembrator 120W sonifier and a 1/8" tip. The miniemulsion was then kept overnight at 40ºC to complete chloroform evaporation.
Nanoparticles and polymers characterization
The z-average diameter (Dz) and polidispersion indexes (PDI) of nanoparticles were determined by Dynamic Light Scattering (Malvern Nanosizer -Nano Series). Progesterone recovery yield (RY %) and encapsulation efficiency (EE %) were determined by High Performance Liquid Chromatography (HPLC, Ultimate 3000, Dionex) in triplicate according to the methodology described by PEREIRA et al. (2000) . The conditions employed to the analysis were the following: methanol:water (75:25, v/v) as mobile phase at 1mL min -1 , column X-bridge (Waters) (C18 5µm 4.6mm x 150mm -37°C) and detection at 245nm. The RY % represents the relation between the total mass of progesterone determined by HPLC (m TP ) and the total mass added in the formulation (m 0 ) (Equation 1). The EE% represents the progesterone actually entrapped inside the nanoparticles (m AP ) (Equation 2).
(1) (2) Infrared spectra of nanoparticles components, progesterone loaded nanoparticles and blank nanoparticles were obtained by scans taken from 4000 to 500cm -1 with 32 accumulations on a Shimadzu (IR AFFINITY-1) spectrometer.
Statistical analysis
Encapsulation recovery, efficiency and the nanoparticles size were evaluated using one-way ANOVA followed by Tukey post hoc test. Differences were considered statistically significant when the p-value was less than 0.05 and the calculations were carried out using Statistica 7.0 (StatSoft, Tulsa, USA).
RESULTS AND DISCUSSION
Recovery yield and encapsulation efficiency of progesterone in the synthesized nanoparticles are presented in table 1. All recovery yields presented high values with no significant difference (p>0.05) meaning that no loss of progesterone during the encapsulation procedure could be observed. SOUZA et al. (2011) results obtained at the present research can be explained by the hydrophobic characteristics of PLLA, PCL and PHBV that present more affinity with progesterone than with the copolymer used by MATSUMOTO et al. (1999) . The addition of hydrophilic segments (PEG) into the hydrophobic PLA homopolymer reduced the encapsulation efficiency. The z-average size (Dz) and polydispersion index (PDI) of the nanoparticles containing progesterone are presented in table 1. All formulations yielded particles in the nanometric range. Also, low polydispersity indexes were found with no significant difference (P>0.05). BYUN et al. (2011) prepared α-tocopherol-loaded PCL nanoparticles by emulsion solvent evaporation using a sonication apparatus. The average nanoparticles size obtained by the authors remained between 247 and 1070nm using poly (vinil alcohol) as surfactant. MUSYANOVYCH et al. (2008) produced PCL nanoparticles with lutensol as surfactant and obtained similar results as those presented in table 1. Figure 1 presents the infrared spectra of all the components used in the nanoparticles preparation along with some characteristic absorption bands. In figure 2 the infrared spectra of the progesteroneloaded and blank nanoparticles are presented.
Lecithin presented a strong band at 2855 cm -1 , a band located at 2930 cm -1 with a shoulder at 2956 cm -1 and a small band at 3010 cm -1 due to the CH stretching (CAVALLARO et al., 1995) . These bands could be found in figure 1 (highlighted  area) . The P-O-C and PO 4-lecithin groups were also found at 1050 cm -1 (RUGGIRELLO and LIVERI, 2003) . CERCHIARA et al. (2003) described that progesterone has characteristic bands located at 1661 cm -1 and 1698 cm -1 corresponding to the carbonyl groups (C3-cyclic and C20-linked to methyl radical). In figure 1 these bands are located at 1656 cm -1 and 1703 cm -1 respectively in progesterone spectra. The characteristic band of the double bond of progesterone is located between 850 and 900 cm -1 (LANCASTER et al., 2007) . Progesterone band located at 870cm -1 is also found in figure 1. For PCL, PLLA and PHBV the characteristic band of polyesters related to the C=O stretching could be found at approximately 1700 cm -1 (POLETTO et al., 2007) . It was possible to observe in figure 2 that for PHBV nanoparticles, in both progesterone-loaded and blank nanoparticles, the lecithin bands related to CH stretching modes are similar to pure lecithin spectra (Figure 1) . However all the other polymeric nanoparticles presented an increase in the intensity of the shoulder located at 2956 cm -1 . This behavior is clearer for PCL and PHBV/PCL nanoparticles. EDWARDS et al. (1993) point out that such behavior indicates an increase in the crystallinity degree of the alkyl side chain of lecithin.
Progesterone bands regarding to C=O stretching at C3 and C20 shifted to 1654cm -1 and 1614cm -1 in all nanoparticles spectra contacting progesterone. According to LIU et al. (2004) the presence of shifts or changes in the polymer-drug spectrum is an indication that they are chemically interacting. DEV et al. (2010) encapsulated lamivudine in PLA and chitosan nanoparticles and compared the FTIR spectra of black nanoparticles to nanoparticles containing the drug. They observed a widening of the lamivudine band located between 1000 and 1100 cm -1 . The authors concluded that this behavior indicated the interaction between the drug and polymer as well as confirms their incorporation into polymeric nanoparticles. In general one can conclude that all formulations interactions took place between progesterone and the biopolymers due to the observed changes in the FTIR spectra. The most evident interaction observed in figure 2 is between progesterone and PHBV/PCL nanoparticles, due to the increase in the intensity and enlargement of the band located at 1631 cm -1 . This is in agreement with the results found by PIMENTEL (2010) that evaluated the progesterone release from PHBV and PHBV/PCL microparticles and found that during 12h of analysis PHBV released up to 95% of the drug while the blends of PHBV/PCL released up to 77% of the drug in the same period. DAS et al. (2010) used FTIR to determine the potential interactions between the components of nanoparticles (alginate, chitosan and pluronic) containing curcumin. SAWANT et al. (2010) demonstrated by FTIR spectra that there was no interaction between the drug lidocaine encapsulated in hydrophobic Eudragit polymers, since the spectrum did not presented any changes with respect to the spectra of the components when analyzed isolated.
CONCLUSION
PHBV, PLLA, PCL as well as PHBV/ PCL and PHBV/PLLA blends demonstrated to be suitable encapsulation agents for progesterone. All the biopolymers and blends used presented narrow size distributions, high encapsulation efficiency and high drug loading, indicating that the technique and the tested biopolymers are indicated for the proposed application. The interactions between progesterone and the polymeric matrix were evidenced by FTIR spectra, showing a stronger interaction with the PHBV/PCL blend.
